MET and non-small cell lung carcinoma: Several landmark papers have demonstrated that NSCLC can harbour different MET alterations (MET+), such as MET overexpression (MET OE), MET phosphorylation (its activated form), MET amplification (MET AMP), or MET gene mutations and that these alterations can negatively affect the patients’ clinical outcomes [18,19,20,21,22,23,24,25,26,27,28,29,30].